Steven R. Schneider

Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TRβ subtype-selective thyromimetics

Robert L. Dow, Steven R. Schneider, Ernest S. Paight et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 93 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Novel Series +7

Discovery of 2-(2-Chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2<i>H</i>-pyrazolo[3,4-<i>f</i>][1,4]oxazepin-8(5<i>H</i>)-one (PF-514273), a Novel, Bicyclic Lactam-Based Cannabinoid-1 Receptor Antagonist for the Treatment of Obesity

Robert L. Dow, Philip A. Carpino, John R. Hadcock et al. · Journal of Medicinal Chemistry · 2009 · 45 citations · Full text

Drug Target, Receptor Antagonists, Food Intake +16

Design of a Potent CB₁Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents

Robert L. Dow, Philip A. Carpino, Denise Gautreau et al. · ACS Medicinal Chemistry Letters · 2012 · 39 citations · Full text

1-((3S,4S)-4-Amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes

Kim Andrews, David A. Beebe, John W. Benbow et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 20 citations · Full text

Medicinal Chemistry, Biochemistry, Medicine +9

Potent and selective, sulfamide-based human β3-adrenergic receptor agonists

Robert L. Dow, Ernest S. Paight, Steven R. Schneider et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 16 citations · Full text

Molecular Pharmacology, Medicine, Physiology +6